Lupin Q1 Results FY25-26: Revenue Up 12% YoY, Net Profit Rises 52%

    Lupin Q1 Results FY25-26: Revenue Up 12% YoY, Net Profit Rises 52%

    Lupin Limited reported a strong set of results for the first quarter of financial year 2025–26 (Q1 FY26), with solid growth in both revenue and profitability. For the quarter ended June 30, 2025, the company achieved a 12% year-on-year (YoY) increase in revenue, reaching ₹6163.8 crore, while net profit surged by 52% YoY to ₹1219.1 crore. The company's operating margin also improved significantly, highlighting an efficient cost structure and higher contribution from complex generics.

    Quick Insights

    • Revenue: ₹6,163.8 crore, up 12% YoY

    • EBITDA: ₹1,641.4 crore, up 27.6% YoY; EBITDA margin rose to 26.6%

    • Net Profit: ₹1,219.1 crore, increased 52.1% YoY

    • As of 6th August, 2025 Lupin share price was ₹1,851.10

    • Gross Profit: ₹4,391.9 crore; margin expanded to 71.3%

    • Other Operating Income: ₹104.5 crore, up 21.6% YoY

    Lupin Limited

    Trade

    2478.535.30 (1.44 %)

    Updated - 20 July 2026
    2494.80day high
    DAY HIGH
    2424.00day low
    DAY LOW
    688779
    VOLUME (BSE)

    Sales Breakdown by Geography:

    Region

    Revenue (₹ crore)

    YoY Growth

    North America

    2,515.5

    23%

    India

    2,089.4

    8%

    EMEA

    626.9

    25%

    APAC

    315.8

    3%

    LATAM

    173.8

    17%

    RoW

    199.3

    29%

    API

    243.1

    33%

    Quarterly - Lupin Q1 Results FY25-26

    The quarter witnessed Lupin’s highest consolidated sales in recent years, backed by sustained performance in the US market, steady growth in India, and a sharp rise in the API and EMEA segments.

    Metric

    Q1 FY26

    Q1 FY25

    YoY Growth

    Net Sales

    ₹6,163.8 crore

    ₹5,514.3 crore

    11.8%

    EBITDA (excl. Fx)

    ₹1,641.4 crore

    ₹1,286.4 crore

    27.6%

    EBITDA Margin

    26.6%

    23.3%

    +330 bps

    Net Profit

    ₹1,219.1 crore

    ₹801.3 crore

    52.1%

    R&D Spend

    ₹208.6 crore

    ₹111.7 crore

    +86.7%

    Capex

    ₹484.4 crore

    ₹350.0 crore

    +38.4%

    Quarter-on-quarter (QoQ), net profit increased by 57.8%, while sales rose 10.8%, indicating strong sequential performance.

    Segment Highlights

    India Business

    • Revenue: ₹2,089.4 crore, up 8% YoY

    • Rx Sales Growth: 8.6% in line with IPM growth

    • Leading therapeutic areas: Cardiology, Respiratory, Gastrointestinal, and Vitamins-Minerals-Supplements (VMS)

    • Anti-diabetes growth was modest at 6.8% due to loss of exclusivity in key products

    • Launched 5 new products; plans 20+ launches in FY26

    • Chronic therapies contributed ~65% to sales

    North America

    • Revenue: ₹2,515.5 crore, up 23% YoY

    • Highest quarterly sales since Q4 FY17

    • Key driver: Launch of Tolvaptan (gJynarque®) with sole 180-day exclusivity

    • Pipeline includes 49 FTFs (19 exclusive), and 100+ new product launches planned till FY30

    • Market share of ~4.5% in US generic prescriptions

    API Segment

    • Revenue: ₹243.1 crore, 33% growth YoY

    • Supported internal formulation needs and external sales

    • Certified by TGA (Australia) and WHO Geneva during the quarter

    Sector Expectations for Lupin Q1 Results FY25-26

    Lupin’s Q1 results outperformed broad sector expectations in terms of margin expansion and profit growth. While many Indian pharma companies faced pricing pressure in the US generics market, Lupin’s performance bucked the trend, aided by exclusive launches and a shift toward complex generics.

    R&D and capex investments also aligned well with sectoral strategies, focusing on inhalation, injectables, and biosimilars—high-value areas expected to drive long-term growth.

    Management Commentary

    The management highlighted consistent improvement in margins driven by operating leverage, product mix optimisation, and strategic launches. Investments in high-complexity products are expected to further enhance profitability and market share.

    Compliance improvements were evident:

    • Nagpur Unit-II: Received Establishment Inspection Report (EIR) from US FDA

    • Pithampur Units: Awaiting response review from US FDA after Form 483 issuance

    • Approvals received from global regulators, including WHO, TGA, and HESSEN (Germany)

    Source: Q1 FY25-26 Quarterly Results uploaded on 6th August, 2025, on BSE.

    For a complete overview of all upcoming and past earnings reports, check the Quarterly Results Calendar 2025.

    Share this article: 

    Published Date : 06 Aug 2025

    Disclaimer :

    Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.


    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.



    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,300 Cr+ MTF Book

    icon-with-text
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |